Mfd. by :- Eli Lilli and Company (Fulfilled By : Magicine Pharma)
Magicine Pharma is registered with the Government Of NCT, India, Ministry Of Health in Government of Delhi, India, registration number DL-RAJ-122372 and as a wholesale distributor, department file No. 44208.
Brand name - Olumiant
Generic name - Baricitinib
Manufacturer - Eli Lilly and Co.
Salt composition - Baricitinib
Disease indication - Rheumatoid arthritis
Storage - Store at 20-25°C (68-77°F)
Dosage form - oral
Strength - 2mg, 4mg
Packaging - bottle of 30 tablets
Gender - Unisex
Indication - used in the treatment of adult patients with moderately to severely active Rheumatoid Arthritis.
Olumiant (baricitinib) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Baricitinib blocks the activity of certain enzymes that are involved in activating inflammation in the body. Olumiant 2 mg tablet is light pink, debossed with “Lilly” on one side and “2” on the other. Olumiant 4 mg tablet is light pink, debossed with “Lilly” on one side and “4” on the other.
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family. They play a crucial role in the proinflammatory pathway signalling that is frequently over-activated in rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib works to disrupt the activation of downstream signalling molecules and proinflammatory mediators.
Baricitinib inhibition of IL-6 induced STAT3 phosphorylation
Baricitinib administration resulted in a dose-dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were seen using either IL-6 or TPO as the stimulus.
Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with Olumiant, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.
C-reactive protein
In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with Olumiant and were maintained throughout dosing.
At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.
The active ingredient in Olumiant is Baricitinib. Other ingredients are croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, iron oxide red, lecithin, macrogol 3350, polyvinyl alcohol, purified talc and titanium dioxide.
Olumiant (Baricitinib Tablet) is used for the treatment of adult patients with active rheumatoid arthritis, who already have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Common cold
Sinus
Shingles
Stomach ache
Weight loss
Feeling tiredness
Sore throat
Skin rash
Muscle pain
Joint pain
Fever and chills
Shortness of breath
Difficulty in breathing
Swelling of the lips and tongue
Increased urination
Pain or burning when you urinate
Chest pain
Rapid breathing
Coughing up pink or red mucus
Night sweats
Swelling or redness in an arm or leg
Change in bowel habits
Skin sores
Unusual sweating
Skip the missed dose if it is already time for the next dose. Do not double the dose to catch up.
Seek emergency medical help in case of overdose.
Before consuming Olumiant (Baricitinib Tablet), make sure to tell your healthcare provider if you:
Already have an infection that doesn’t go away easily or are being treated for an infection.
Have TB or have been in close contact with someone with TB.
Have or have had hepatitis B or C
Have cancer
Have blood clots in the veins of your legs or lungs.
Have kidney or liver problems
Have diabetes
Have lung disease
Have HIV
Have a weak immune system
Have any stomach-area pain
Have been diagnosed with inflammation in the large intestine or ulcers in your stomach or intestines.
Have recently received a vaccine
Are planning to receive a vaccine
Are pregnant
Are planning to become pregnant
Are breastfeeding or planning to breastfeed.
Are taking other medicines, including prescribed supplements.
Are under age 18 (because it is not known if Olumiant is safe and effective in children).
It is not known if Olumiant is safe and effective in children (below age 18).
It is recommended to not consume Olumiant (Baricitinib Tablet) during breastfeeding.
A- Olumiant (Baricitinib Tablet) is used for the treatment of adult patients with active rheumatoid arthritis.
A- Take Olumiant (Baricitinib Tablet) exactly as your healthcare provider tells you.
A- There can be side effects such as fever, chills, muscle and joint pain, stomach pain, diarrhea, coughing up red mucus, rashes, sinus, difficulty in breathing and weight loss. If you experience these or any other side effects, please contact your healthcare provider.
A- Baricitinib Tablet is available in the strength of 2mg and 4mg.
A- Skip the missed dose if it is already time for the next dose. Do not double the dose to catch up.
A- Do not receive a "live" vaccine while using Olumiant. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), and zoster (shingles).
A- Keep a note of all the side effects you experience and tell your healthcare provider.
A- Please consult your healthcare provider.
A- Baricitinib Tablet may cause tiredness. If you experience such side effects, avoid driving and operating heavy machines.
A- Store at 20-25°C (68-77°F).
Fill the Form
Talk to Executive
Get Tracking
Get Medicines Delivered
